R. Todd Stravitz, Mitchell L. Shiffman, Arun J. Sanyal, Velimir A. Luketic, Richard K. Sterling, Douglas M. Heuman, April Ashworth, A. Scott Mills, Melissa Contos, Adrian H. Cotterell, Daniel Maluf, Marc P. Posner, Robert A. Fisher – 29 June 2004 – Recurrent hepatitis C after liver transplantation remains a significant cause of graft loss and retransplantation.

Hendrik K.F. van Saene, Durk F. Zandstra – 29 June 2004

Florence Wong, Lavinia Pantea, Kenneth Sniderman – 2 June 2004 – Hepatorenal syndrome (HRS) is a functional renal disorder complicating decompensated cirrhosis. Treatments to date, except liver transplantation, have been able to improve but not normalize renal function. The aim of this study was to determine the efficacy of transjugular intrahepatic portosystemic stent shunt (TIPS) as a treatment for type 1 HRS in ascitic cirrhotic patients, following improvement in systemic hemodynamics with a combination of midodrine, octreotide, and albumin (medical treatment).

Keiji Hisaeda, Akihiko Inokuchi, Takanori Nakamura, Yukihide Iwamoto, Kimitoshi Kohno, Michihiko Kuwano, Takeshi Uchiumi – 27 May 2004 – The human multidrug resistance protein 2 (MRP2/ABCC2), expressed on the bile canalicular membrane, mediates the multispecific efflux of several organic anions, including conjugates of glucuronate, sulfate, and glutathione. Expression of MRP2 can be altered in response to environmental stimuli such as cholestasis and jaundice.

Jeffery L. Smith, Peter J. Lewindon, Anita C. Hoskins, Tamara N. Pereira, Kenneth D. R. Setchell, Nancy C. O'Connell, Ross W. Shepherd, Grant A. Ramm – 27 May 2004 – Focal biliary cirrhosis causes significant morbidity and mortality in cystic fibrosis (CF). Although the mechanisms of pathogenesis remain unclear, bile acids have been proposed as potential mediators of liver injury. This study examined bile acid composition in CF and assessed altered bile acid profiles to determine if they are associated with incidence and progression of liver injury in CF‐associated liver disease (CFLD).

Andrew K Burroughs, Ulrich Thalheimer, Maria Mela, David Patch – 27 May 2004

Jae‐Sung Kim, Shigetoshi Ohshima, Peter Pediaditakis, John J. Lemasters – 27 May 2004 – We investigated the effects of nitric oxide (NO) on hepatocellular killing after simulated ischemia/reperfusion and characterized signaling factors triggering cytoprotection by NO. Cultured rat hepatocytes were incubated in anoxic Krebs‐Ringer–HEPES buffer at pH 6.2 for 4 hours and reoxygenated at pH 7.4 for 2 hours.

Lennox J. Jeffers, William Cassidy, Charles D. Howell, Sylvia Hu, K. Rajender Reddy – 27 May 2004 – Black Americans (blacks) have a high prevalence of chronic hepatitis C virus (HCV) infection and respond poorly to therapy with interferon alfa‐based regimens, but they have been underrepresented in clinical trials. The aim of this study was to assess the rate of sustained virological response (SVR) to peginterferon alfa‐2a (40 kd) in combination with ribavirin in black patients chronically infected with HCV genotype 1.

Susan E. Crawford – 27 May 2004

Man‐Fung Yuen, Danny Ka‐Ho Wong, Erwin Sablon, Eric Tse, Irene Oi‐Lin Ng, He‐Jun Yuan, Chung‐Wah Siu, Tamara J. Sander, Eric J. Bourne, Jeff G. Hall, Lynn D. Condreay, Ching‐Lung Lai – 27 May 2004 – Few studies have examined Chinese patients with chronic hepatitis B who exhibit hepatitis B surface antigen (HBsAg) seroclearance. We comprehensively studied the biochemical, virological, histological, and clinical aspects of 92 patients with HBsAg seroclearance (median follow‐up, 126 months).